Myeloid Neoplasm Post Cytotoxic Therapy

Myeloid Neoplasm Post Cytotoxic Therapy — Trials · CancerIndex

Clinical trials

Registered studies

65 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 20
Recruiting: 7
Ph III recruiting: 0
Growth YoY: —
Industry share: 10%
Top sponsor: National Cancer Institute (NCI)
Termination share: 24.3%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (9)

clinicaltrialsPublishedShowing 51–65 of 65 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03602898	Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation	withdrawn	Phase 2	0	Fred Hutchinson Cancer CenterOTHER	1	Jun 30, 2021	clinicaltrials
NCT01307579	Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia	completed	Phase 3	517	Children's Oncology GroupNETWORK	3	Mar 30, 2021